RARA CRAFT DATABASE for FDA Medical Devices
510(k)K231620

FDA DEVICE FACTS

Nuubo Smart

Smart Solutions Technologies SL

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEAugust 1, 2023PRODUCT CODEDQK

Indications for use

The Nuubo Smart is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. The Nuubo Smart continuously records and stores ECG and activity data for up to 30 days at a time. The Nuubo Smart detects arrhythmias at the end of each monitoring day upon download of the ECG data. The Nuubo Smart is Rx use device The Nuubo System is indicated for use on patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. The Nuubo system continuously records and stores ECG and activity data for upto 30 days at a time. The Nuubo System detects arrhythmias at the end of the monitoring period upon download of the ECG data. The Nuubo System is a Rx use device. The NUVANT (SEEQ) System is intended to continuously measure, record and periodically transmit physiological data. The System is indicated for those patients who require monitoring for the detection of non-lethal cardiac arrhythmias such as, but not limited to, supraventricular tachycardias (e.g. atria] fibrillation, atrial flutter, paroxysmal SVTs), ventricular ectopy, bradyarrhythmias and conduction disorders. The NUVANT System monitors, derives and displays: * ECG * Heart Rate

The Indications for Use statement for the Nuubo Smart differs slightly from that of the primary predicate device to address automatically detected events daily and not at the end of the monitoring; however, these differences do not alter the intended use of the device. Collectively, the subject device has the same intended use in cardiac arrhythmia diagnostics as the two predicate devices. The Indications for Use statement for the Nuubo Smart differs slightly from the secondary predicate device (SEEQ). Both systems are indicated for the same population and detection of non-lethal cardiac arrhythmias, but the indications of use of Nuubo Smart are stated in terms of symptoms referred by the patient instead of arrhythmias detected. The SEEQ System refers in the manual that, based on the indications, the system could be used in “patients with symptoms such as chest pain, syncope, light-headedness or near syncope, vertigo, dizziness, fall, palpitations, transient ischemic episodes, and dyspnea (shortness of breath) that might be due to cardiac arrhythmias”, which are nearly the same as Nuubo Smart. The type of arrhythmias detected are the same in both systems.

Differences in the proposed Indications for Use statement does not affect the safety and effectiveness profile of the subject device relative to the predicate devices. Therefore, the subject device can be considered substantially equivalent to the predicate devices.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026